936940-15-7

Basic information

• Product Name: 1-(1H-pyrazol-1-yl)propan-2-amine
• Synonyms: 1-(1H-pyrazol-1-yl)propan-2-amine;1-METHYL-2-PYRAZOL-1-YL-ETHYLAMINE;OTAVA-BB 7020610549;VITAS-BB TBB008942;1-(1H-pyrazol-1-yl)propan-2-amine(SALTDATA: FREE);[1-Methyl-2-(1H-pyrazol-1-yl)ethyl]amine
• CAS NO: 936940-15-7
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.17
• Mol File: 936940-15-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 214.6°C at 760 mmHg
• Flash Point: 83.6°C
• Appearance: /
• Density: 1.11g/cm³
• Vapor Pressure: 0.155mmHg at 25°C
• Refractive Index: 1.564
• CAS DataBase Reference: 1-(1H-pyrazol-1-yl)propan-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1H-pyrazol-1-yl)propan-2-amine(936940-15-7)
• EPA Substance Registry System: 1-(1H-pyrazol-1-yl)propan-2-amine(936940-15-7)

Safety Data

• Hazardous Substances Data: 936940-15-7(Hazardous Substances Data)

Usage

Description

1-(1H-pyrazol-1-yl)propan-2-amine, also known as PZP, is a chemical compound with the molecular formula C6H10N4. It is a derivative of the pyrazole family and belongs to the class of amines. PZP is a psychoactive substance that has been researched for its potential pharmacological properties, particularly in the field of neuroscience and neuropsychopharmacology. It has been studied for its effects on neurotransmitter systems and its potential role in modulating synaptic transmission.
Used in Pharmaceutical Industry:
1-(1H-pyrazol-1-yl)propan-2-amine is used as a research compound for its potential therapeutic applications, particularly in the treatment of mood disorders and psychiatric conditions. Its effects on neurotransmitter systems and potential role in modulating synaptic transmission make it a promising candidate for further investigation and development in the field of neuroscience and neuropsychopharmacology.
Used in Research and Development:
1-(1H-pyrazol-1-yl)propan-2-amine is used as a chemical intermediate in the synthesis of other compounds with potential pharmacological properties. Its unique structure and reactivity make it a valuable building block for the development of new drugs and therapeutic agents.

InChI:InChI=1/C6H11N3/c1-6(7)5-9-4-2-3-8-9/h2-4,6H,5,7H2,1H3

Upstream product

• 1134102-27-4 C₆H₉N₃O 

Relevant articles and documents

3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE'S AND 3-SUBSTITUTED 1,3-PYRIMIDINONE'S FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson''s disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke- induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi''s syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.